Health
Opaganib shows promise in preventing ARDS-induced thrombosis – Drug Target Review
Opaganib reduced blood clot length and weight in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
Posted: 16 December 2020 | Hannah Balfour (Drug Target Review) | No comments yet
Opaganib reduced blood clot length and weight in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
Opaganib (Yeliva®), a novel, orally administered sphingosine kinase 2 (SK2) selective inhibitor, (administered at 250mg/kg,) reduced thrombosis in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
According to the researchers, their findings suggest opaganib may be of benefit to patients…
-
Business20 hours agoWhy Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today
-
Noosa News22 hours agoBroncos staffer who guided Mam through crash crisis admits to drink-driving
-
Noosa News23 hours agoQueenslanders to continue legal challenges against COVID-19 directives after successful appeal
-
Noosa News15 hours agoRacing Queensland responds to criticism of ‘deadliest’ greyhound track